[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Jin J, Xu X, Wang F, Yan G, Liu J, Lu W, Li X, Tucker SJ, Zhong B, Cao Z, Wang D: Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol; 2009 Aug;4(8):1017-21
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
  • BACKGROUND: There is an urgent need for an effective second-line chemotherapy regimen after failure of the standard cisplatin and 5-fluorouracil therapy.
  • PATIENTS AND METHODS: This study investigated the efficacy and toxicity of the combination of docetaxel (30 mg/m2) during a 1-hour infusion, followed by nedaplatin (50 mg/m2) during a 2-hour infusion (both drugs were administered on day 1 as an outpatient regimen and repeated every 2 weeks) as second-line chemotherapy for patients with cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma after surgery.
  • The median overall time to progression and overall survival was 3.1 months (95% CI, 2.3-3.9 months) and 5.9 months (95% CI, 3.9-7.8 months), respectively.
  • CONCLUSIONS: The combination chemotherapy of docetaxel and nedaplatin in the outpatient setting is well tolerated and useful as second-line chemotherapy for cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Drug Resistance, Neoplasm. Esophageal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Prognosis. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542899.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; 8UQ3W6JXAN / nedaplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Tachimori Y, Kanamori N, Uemura N, Hokamura N, Igaki H, Kato H: Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg; 2009 Jan;137(1):49-54
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma.
  • OBJECTIVE: Chemoradiotherapy is a popular definitive therapy for esophageal carcinoma among many patients and oncologists.
  • Although the complete response rates are high and short-term survival is favorable after chemoradiotherapy, persistent or recurrent locoregional disease is frequent.
  • Salvage surgery is the sole curative intent treatment option for this course of the disease.
  • The present study evaluates the safety and value of salvage esophagectomy for locoregional failure after high-dose definitive chemoradiotherapy for esophageal squamous cell carcinoma.
  • METHODS: We reviewed 59 consecutive patients with thoracic esophageal squamous cell carcinoma who underwent salvage esophagectomy after definitive chemoradiotherapy.
  • All patients received more than 60 Gy of radiation plus concurrent chemotherapy for curative intent.
  • The data were compared with those of patients who received esophagectomy without preoperative therapy.
  • RESULTS: Postoperative morbidity and mortality rates were increased among patients who underwent salvage esophagectomy compared with those who underwent esophagectomy without preoperative therapy (mean hospital stay, 38 vs 33 days; anastomotic leak rates, 31% vs 25%; respiratory complication rates, 31% vs 20%; reintubation within 1 week, 2% vs 2%; hospital mortality rates, 8% vs 2%).
  • CONCLUSION: Patients who underwent salvage esophagectomy after definitive high-dose chemoradiotherapy had increased morbidity and mortality.
  • Such treatment should be considered for carefully selected patients at specialized centers.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19154902.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Makino H, Tajiri T, Onda M, Sasajima K, Miyashita M, Nomura T, Maruyama H, Nagasawa S, Tsuchiya Y, Hagiwara N, Yamashita K, Takubo K: Effectiveness of preoperative chemotherapy using carboplatin (CBDCA) and surgery against an esophageal small cell carcinoma. Dis Esophagus; 2002;15(3):237-41
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of preoperative chemotherapy using carboplatin (CBDCA) and surgery against an esophageal small cell carcinoma.
  • An endscopically obtained biopsy specimen was found to represent undifferentiated small cell carcinoma.
  • Computed tomography of the chest, abdomen, and cervical region was performed, as were gallium and bone scintigraphy.
  • After neoadjuvant chemotherapy with carboplatin (CBDCA) (400 mg/m2) and etoposide (VP-16) (100 mg/m2), endoscopy and barium-swallow esophagography showed regression.
  • Thoracic esophagectomy then was performed with mediastinal, abdominal and cervical lymph node dissection.
  • The lesion consisted mainly of small anaplastic cells, but included a small focus of squamous cell carcinoma.
  • The patient has survived for more than 7 months with no further treatment and no evidence of recurrent disease.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12444997.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


Advertisement
4. Doki Y, Ishikawa O, Takachi K, Miyashiro I, Sasaki Y, Ohigashi H, Murata K, Yamada T, Noura S, Eguchi H, Kabuto T, Imaoka S: Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma. World J Surg; 2005 Jun;29(6):700-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma.
  • The site of surgical failure in cases of thoracic esophageal cancer (TEC) may be affected by the vertical location of the cancer in this longitudinal organ, suggesting the need to select the mode of adjuvant therapy based on location.
  • We classified 501 TECs (92% squamous cell carcinomas) that underwent curative surgery without preoperative treatment as 13% upper thoracic (Ut), 51% middle thoracic (Mt), and 36% lower thoracic (Lt) lesions.
  • Recurrent disease was discovered in 180 (36%) of the patients during a postoperative survey, most frequently in the cervical nodes (19%), liver (18%), abdominal paraaortic nodes (17%), and upper mediastinal nodes (17%).
  • Thus the vertical location of the thoracic esophageal cancer can be said to affected strongly the site of tumor recurrence after curative surgery.
  • Regional radiotherapy might be expected to have an adjuvant effect on Ut/Mt tumors and systemic chemotherapy on Lt tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Abdomen. Esophagectomy. Humans. Lymph Node Excision. Mediastinum. Neck. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 11):11-8 [14506599.001]
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):340-6 [8605557.001]
  • [Cites] Dis Esophagus. 2001;14(2):98-103 [11553217.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1315-8 [11100340.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1989 Mar;90(3):364-76 [2770680.001]
  • [Cites] Hepatogastroenterology. 2003 Jan-Feb;50(49):115-20 [12630005.001]
  • [Cites] Recent Results Cancer Res. 2000;155:123-33 [10693246.001]
  • [Cites] Dis Esophagus. 2001;14(3-4):191-6 [11869318.001]
  • [Cites] Surgery. 2001 Nov;130(5):792-7 [11685188.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):364-72; discussion 372-3 [8092902.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 9):46-55 [12908136.001]
  • [Cites] World J Surg. 1997 Mar-Apr;21(3):275-81 [9015170.001]
  • [Cites] Oncol Rep. 2003 Jan-Feb;10(1):81-7 [12469149.001]
  • [Cites] World J Surg. 1994 Mar-Apr;18(2):266-72 [8042333.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 May;15(3):98-108 [12801045.001]
  • [Cites] Surgery. 2002 Jul;132(1):93-9 [12110801.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):581-7 [11685019.001]
  • [Cites] J Am Coll Surg. 2000 Sep;191(3):232-7 [10989896.001]
  • [Cites] Gan To Kagaku Ryoho. 1995 Sep;22(11):1538-41 [7574753.001]
  • [Cites] Surgery. 2003 Apr;133(4):368-74 [12717353.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Jan;11(1):89-109, viii [11928803.001]
  • [Cites] Am J Surg. 1999 Jun;177(6):503-6; discussion 507 [10414703.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1616-23 [12655517.001]
  • [Cites] Surgery. 2003 May;133(5):479-85 [12773975.001]
  • (PMID = 16078126.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Lee PC, Port JL, Paul S, Stiles BM, Altorki NK: Predictors of long-term survival after resection of esophageal carcinoma with nonregional nodal metastases. Ann Thorac Surg; 2009 Jul;88(1):186-92; discussion 192-3
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of long-term survival after resection of esophageal carcinoma with nonregional nodal metastases.
  • BACKGROUND: Patients with esophageal carcinoma and celiac, cervical, or other nonregional nodal metastases generally have a poor prognosis after surgical resection.
  • METHODS: We conducted a retrospective review of a prospective database over a 20-year period to identify patients with resected esophageal carcinoma with nonregional lymph node metastases.
  • Sites of nodal metastases were the following: recurrent nodal chain in 42 patients, celiac in 20, both recurrent and celiac in 4, and paratracheal in 1.
  • Patients treated with induction chemotherapy had prolonged 5-year survival (41%, p = 0.06) compared with those treated with adjuvant chemotherapy (11%) or no therapy (20%).
  • Multivariate analysis demonstrated that chemotherapy treatment, squamous cell type, and early T stage (pT1/T2) are significant positive predictors of survival.
  • CONCLUSIONS: Surgical resection for patients with esophageal cancer associated with nonregional nodal metastases results in 25% survival at five years.
  • Squamous histology, earlier T status, and perioperative chemotherapy are independent positive predictors of long-term survival.
  • [MeSH-major] Cause of Death. Esophageal Neoplasms / mortality. Esophageal Neoplasms / surgery. Esophagectomy / mortality. Lymph Nodes / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Cohort Studies. Female. Follow-Up Studies. Hospital Mortality. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Proportional Hazards Models. Registries. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19559222.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


6. Swanson SJ, Batirel HF, Bueno R, Jaklitsch MT, Lukanich JM, Allred E, Mentzer SJ, Sugarbaker DJ: Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg; 2001 Dec;72(6):1918-24; discussion 1924-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma.
  • BACKGROUND: Several techniques for esophageal resection have been reported.
  • This study examines the morbidity, mortality, and early survival of patients after transthoracic esophagectomy for esophageal carcinoma using current staging techniques and neoadjuvant therapy.
  • The technique includes right thoracotomy, laparotomy, and cervical esophagogastrostomy (total thoracic esophagectomy) with radical mediastinal and abdominal lymph node dissection.
  • METHODS: Three hundred forty-two patients had surgery for esophageal carcinoma between 1989 and 2000 at our institution.
  • Eighty-one percent (202) had induction chemotherapy (all patients with clinical T3/4 or N1).
  • Early postoperative complications included recurrent laryngeal nerve injury (14% [35]), chylothorax (9%, [22]), and leak (8%, [19]).
  • CONCLUSIONS: Total thoracic esophagectomy with node dissection for esophageal cancer appears to have acceptable morbidity and mortality with encouraging survival results in the setting of neoadjuvant therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Gastrostomy / methods. Lymph Node Excision / methods. Precancerous Conditions / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11789772.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


7. Nakamura T, Ota M, Narumiya K, Sato T, Ohki T, Yamamoto M, Mitsuhashi N: Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol; 2008 Sep;15(9):2451-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection.
  • BACKGROUND: Although esophagectomy with extended lymph node dissection can improve survival of patients with esophageal carcinoma, lymph node metastasis has remained one of the main recurrence patterns.
  • The aim of this study was to evaluate the outcome of intensive treatment for recurrent lymph node metastasis.
  • METHODS: Recurrent lymph node metastasis was detected in 68 patients with thoracic esophageal carcinoma after curative esophagectomy (R0, International Union Against Cancer criteria).
  • Multimodal treatment was performed in 41 patients: 19 patients underwent lymphadenectomy with adjuvant therapy, and 22 received definitive chemoradiotherapy and repeated chemotherapy.
  • The remaining 27 patients (40%) received chemotherapy or best supportive care.
  • RESULTS: Survival of the lymphadenectomy and the chemoradiotherapy groups was significantly better than that of the patients who received chemotherapy or best supportive care (P < .0001).
  • The most common repeat recurrence pattern was organ metastasis after the treatment.
  • CONCLUSION: Multimodal treatment including lymphadenectomy and chemoradiotherapy could improve survival of the patients with lymph node recurrence of esophageal carcinoma after curative resection.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Esophagectomy. Lymph Node Excision. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592318.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Jiang YY, Wu SX, Zhang P, Xie CY, Wang J, Sun CC: [Concurrent standard dose of cisplatin, paclitaxel, and radiotherapy followed by surgery in treatment of thoracic esophageal carcinoma]. Zhonghua Yi Xue Za Zhi; 2008 Aug 12;88(31):2171-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concurrent standard dose of cisplatin, paclitaxel, and radiotherapy followed by surgery in treatment of thoracic esophageal carcinoma].
  • OBJECTIVE: To investigate the curative effect of incorporation of the regimen of standard dose of paclitaxel combined with cisplatin into concurrent radiotherapy as pre-operative treatment for patients with esophageal carcinoma.
  • METHODS: Twenty-six patients with primary diagnosis of esophageal carcinoma, 17 in stage II and 9 in stage III, underwent conventional fractionated radiotherapy with a total dosage of 40 Gy (2 Gy per day, 5 doses per week).
  • 4 - 6 weeks after the completion of chemo-radiotherapy, left thoracic incision and transhiatal esophagectomy with anastomosis in the neck was performed.
  • Surgery-related complications included anastomotic leakage (3.85%, 1/26), recurrent laryngeal nerve injury (7.69%, 2/26), and chylothorax (3.85%, 1/26).
  • CONCLUSION: Preoperative chemoradiotherapy containing full dose of paclitaxel and cisplatin increases the 5-year overall survival for the patients with postoperative pathologic response grade II and above, and does not increase the treatment-related complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Esophagectomy. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Paclitaxel / administration & dosage. Radiotherapy. Young Adult

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080664.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Hara T, Hirano M, Nozawa H, Nakada K, Hirano Y, Oyama K, Hada T, Takagi T, Kikkawa H: [A case of recurrent esophageal cancer successfully treated with weekly paclitaxel in combination with radiotherapy]. Gan To Kagaku Ryoho; 2005 Jun;32(6):829-31
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent esophageal cancer successfully treated with weekly paclitaxel in combination with radiotherapy].
  • A 48-year-old man underwent subtotal esophagectomy for pStage III (pT 3 pN 3) thoracic esophageal carcinoma on June 20, 2002, in combination with chemotherapy (5-FU 500 mg/day day 1-14, CDDP 10 mg/day day 1-14, VDS 3 mg on days 1 and 8) before and after the operation.
  • Chemo (same regimen)-radiotherapy (50 Gy) was then performed but without effect.
  • Thereafter, lung and upper mediastinal metastases were found, and weekly administration of paclitaxel (70 mg/m2, day 1, 8, 15, q 4w) was initiated in combination with radiotherapy (40 Gy).
  • Two cycles of treatment resulted in PR, and CR was achieved after the 8th cycle was completed.
  • Although treatment was terminated after the 12 th cycle due to development of peripheral neuropathy (grade 2), CR was still maintained 8 months after the completion of treatment.
  • These results suggested the effectiveness of the treatment in cases that show resistance to conventional 5-FU-based chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / radiotherapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Drug Administration Schedule. Esophagectomy. Humans. Male. Middle Aged. Peripheral Nervous System Diseases / chemically induced. Radiotherapy Dosage. Remission Induction

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15984525.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Tokumitsu Y, Yamamoto T, Kitamura Y, Ando S, Tsushimi K, Tangoku A: [A case of mediastinoscope-assisted transhiatal esophagectomy for thoracic esophageal cancer after radical operation for lung cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2445-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of mediastinoscope-assisted transhiatal esophagectomy for thoracic esophageal cancer after radical operation for lung cancer].
  • We herein report a case of thoracic esophageal cancer operated on by mediastinoscope-assisted transhiatal esophagectomy after a right upper lobectomy for primary lung cancer.
  • A 70-year-old male with non-small-cell lung cancer (T4N2M0, cStage III B) underwent chemo-radiation therapy followed by an upper lobectomy of the right lung with mediastinal lymph node dissection.
  • Five years after the operation of lung cancer, esophageal cancer (T3N0M0, cStage II) was endoscopically detected in this patient.
  • Partial remission was obtained after neoadjuvant FP chemotherapy for esophageal cancer.
  • Preventive tracheostomy was performed because of recurrent nerve paralysis, but no other severe postoperative complication has developed in this case.
  • Histopathological findings showed a well differentiated squamous cell carcinoma (pT3 (Ad), pN0, M0, pStage II), with involvement at resection margin.
  • He was alive for 11 months after the operation for esophageal cancer, although a local recurrence was observed.
  • There are still many problems remained of the treatment for esophageal cancer patients who had previously undergone a radical operation for lung cancer.
  • However, mediastinoscope-assisted transhiatal esophagectomy may become a procedure for surgical approach if it seems to be difficult to approach the esophageal cancer by thoracotomy again.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Lung Neoplasms / surgery. Mediastinoscopy. Pneumonectomy

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037451.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Minashi K, Ohtsu A, Mera K, Yoshida S, Ishikura S, Ogino T, Boku N, Miyata Y, Kaneko K, Nakamura A: Long-term toxicity and survival of definitive chemoradiotherapy (CRT) in patients (pts) with T4/M1LYM esophageal carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):4209

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term toxicity and survival of definitive chemoradiotherapy (CRT) in patients (pts) with T4/M1LYM esophageal carcinoma.
  • : 4209 Background: Although definitive CRT is considered to be standard of care in non-surgical treatment for loco-regional esophageal carcinoma, there have been few reports indicating the treatment results for locally advanced disease.
  • We have previously reported a multicenter phase II trial of the definitive CRT in pts with T4/M1LYM (UICC1987) esophageal carcinoma, which resulted in median survival time of 9months and 3-year survival rate of 23% despite substantial toxicities (Ohtsu et al.JCO'99).
  • METHODS: Eligibility criteria of this study required T4 and/or M1LYM squamous cell carcinoma of the thoracic esophagus, age ≤ 75, PS 0-2, no prior therapy, and written informed consent.
  • The treatment consisted of 5-FU combined with CDDP and concurrent radiotherapy of 60Gy.
  • For responders, 2 additional courses of chemotherapy were administered.
  • Of the 18 CR pts, grade 3 or worse cardiopulmonary toxicity occurred in 5 (26%) pts: cardiotoxicity in 3 (17%), pleural effusion in 4 (22%), and esophageal stricture in 2 (11%) pts.
  • Eleven of the 18 pts have already died: 7 due to recurrent disease, 3 other malignancies (lung, pancreas, and acute leukemia), and 1 cardiac failure.
  • Seven pts are still alive with no evidence of disease 5.8-8.2 years after initiation of the CRT including 1 pt on-therapy for late toxicity.
  • CONCLUSIONS: Definitive CRT provided 17% 5-year survival rate even for unresectable T4/M1LYM esophageal carcinoma, although late toxicity was non-negligible issues that should be addressed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013936.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Matsubara T, Ueda M, Kaisaki S, Kuroda J, Uchida C, Kokudo N, Takahashi T, Nakajima T, Yanagisawa A: Localization of initial lymph node metastasis from carcinoma of the thoracic esophagus. Cancer; 2000 Nov 1;89(9):1869-73
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of initial lymph node metastasis from carcinoma of the thoracic esophagus.
  • BACKGROUND: Most surgeons consider esophageal carcinoma with lymph node involvement a systemic disease.
  • The regional lymph nodes were divided into the thoracocervical junction group (lower deep cervical and recurrent nerve lymph nodes), perigastric group, and intrathoracic group.
  • RESULTS: Lymph node involvement was limited to a solitary lymph node in 46% of lymph node positive patients with esophageal carcinoma confined to the wall (T1 and T2, UICC) and in 17% of lymph node positive patients with cancer that invaded the extramural layer (T3 and T4, UICC).
  • Most of the 5-year survivors had involvement of a thoracocervical junction or perigastric lymph node and had not received systemic chemotherapy.
  • Systematic dissection of the regional lymph nodes including thoracocervical junction and perigastric groups is recommended for resectable esophageal carcinoma at this time.
  • [MeSH-major] Esophageal Neoplasms / pathology. Lymphatic Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 11064342.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


13. Ehara K, Tsutsumi K, Kinoshita Y, Ueno M, Mine S, Udagawa H: [A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1375-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU].
  • The combination chemotherapy with docetaxel/CDDP/5-FU(DCF)for head and neck squamous carcinoma(SCC) has been widely accepted.
  • It seems quite natural that DCF therapy is expected to be equally effective against esophageal SCC because of their histological similarity.
  • In this report, we present a case of unresectable advanced esophageal SCC with multiple liver metastases which showed remarkable regression by DCF therapy, with relatively slight adverse effects.
  • The patient was a 46-year-old female, who underwent upper gastrointestinal fiber-optic endoscopy for dysphasia and was diagnosed to have upper middle thoracic esophageal SCC.
  • The clinical stage diagnosis was T3N4M1, Stage IVB, obviously non-resectable far-advanced esophageal SCC.
  • Systemic chemotherapy with DCF was started as the initial treatment.
  • The chemotherapy regimen was as follows.
  • Each course was followed by a 23-day drug-free period, and the entire course was repeated every 28 days.
  • Ten cycles of this DCF chemotherapy were carried out.
  • Until this writing, we added 2 more cycles of DCF therapy for the recurrent para-aortic and inguinal lymph node metastasis.
  • We conclude that DCF therapy is potentially very effective for advanced esophageal SCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology. Fluorouracil / therapeutic use. Liver Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / blood. Esophagoscopes. Female. Humans. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed


14. Aujesky R, Neoral C, Kral V, Bohanes T, Vrba R, Vomackova K: Video-assisted laparoscopic resection of the esophagus for carcinoma after neoadjuvant therapy. Hepatogastroenterology; 2009 Jul-Aug;56(93):1035-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Video-assisted laparoscopic resection of the esophagus for carcinoma after neoadjuvant therapy.
  • BACKGROUND/AIMS: Classical operation approaches, used for decades during subtotal esophageal resection for esophageal carcinoma, have certain disadvantages.
  • METHODOLOGY: Between 2000-2006 forty-three patients with esophageal cancer underwent video-laparoscopic transhiatal esophagectomy.
  • Prior to the operation, 27 patients underwent neoadjuvant radio-chemotherapy.
  • Chemotherapy consisted of 5 fluorouracil and cisplatinum, and radiotherapy with a total dose of 50 Gy.
  • Right-sided pneumothorax was seen in 27 patients, in six cases postoperative manifestation of left vocal chord paresis due to damage to the recurrent laryngeal nerve was observed, in 2 patients a fistula developed in the cervical anastomosis, which in all cases healed spontaneously.
  • The operation time ranged between 225-370 minutes, the average time being 256 minutes.
  • CONCLUSIONS: The video-assisted laparoscopic transhiatal approach proved to be very useful during subtotal esophageal resection.
  • In tumors localized in the lower portion of the esophagus, it completely replaces the transhiatal "blind" approach according to Orringer and, in comparison, eliminates operative hemorrhagic complications, which are more frequent in "blind" extirpations, especially in patients after neoadjuvant therapy.
  • In tumors of the middle thoracic esophagus, which are inaccessible by the original Orringer's approach, it eliminates the need for a thoracotomy, which significantly contributes to the decrease of respiratory complications.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy / methods. Laparoscopy / methods. Video-Assisted Surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760936.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Chae EJ, Seo JB, Kim SY, Do KH, Heo JN, Lee JS, Song KS, Song JW, Lim TH: Radiographic and CT findings of thoracic complications after pneumonectomy. Radiographics; 2006 Sep-Oct;26(5):1449-68
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiographic and CT findings of thoracic complications after pneumonectomy.
  • Pneumonectomy is the treatment of choice for bronchogenic carcinoma and intractable end-stage lung diseases such as tuberculosis and bronchiectasis, but it is often followed by postoperative complications, which account for significant morbidity and mortality.
  • Knowledge of the radiologic features of such complications is of critical importance for their early detection and prompt management.
  • Late postpneumonectomy complications include recurrent disease, infection, effects of radiation therapy or chemotherapy, and surgical complications such as late-onset bronchopleural fistula, postpneumonectomy syndrome, and esophagopleural fistula.
  • When the radiographic findings are inconclusive, computed tomography is helpful for establishing a diagnosis and obtaining detailed information about the disease process.
  • [MeSH-major] Bronchial Diseases / etiology. Bronchial Diseases / radiography. Esophageal Diseases / etiology. Esophageal Diseases / radiography. Lung Diseases / etiology. Lung Diseases / radiography. Pneumonectomy / adverse effects
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Prognosis. Thoracic Diseases / etiology. Thoracic Diseases / radiography. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bronchial Disorders.
  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2006.
  • (PMID = 16973775.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


16. Siersema PD, Rosenbrand CJ, Bergman JJ, van der Gaast A, Goedhart C, Richel DJ, Stassen LP, Tilanus HW: [Guideline 'Diagnosis and treatment of oesophageal carcinoma']. Ned Tijdschr Geneeskd; 2006 Aug 26;150(34):1877-82
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Guideline 'Diagnosis and treatment of oesophageal carcinoma'].
  • An evidence-based guideline for the diagnosis and treatment of oesophageal carcinoma was developed on the initiative of the Netherlands Society of Gastroenterohepatology in cooperation with the Dutch Institute for Healthcare Improvement (CBO) and the Dutch Association of Comprehensive Cancer Centres.
  • If a patient with oesophageal carcinoma is eligible for treatment with curative intent, they should undergo thoracic and abdominal CT, ultrasound investigation of the supraclavicular region and endoscopic ultrasonography for staging purposes.
  • Endoscopic therapy is the preferred treatment for high-grade dysplasia or early cancer in Barrett's oesophagus confined to the mucosa.
  • If resection of the oesophageal carcinoma is performed with curative intent, one should aim for radical resection.
  • The type and extent of the resection depends on the location of the tumour.
  • There is evidence that the mortality rate following surgery can be reduced by performing it in centres with ample experience with oesophageal cancer surgery.
  • Preoperative chemotherapy and radiotherapy may improve survival in patients with oesophageal carcinoma.
  • Palliative treatment for oesophageal carcinoma should be considered in cases of local invasion of surrounding organs, metastases, poor physical condition of the patient or recurrent disease after previous curative treatment.
  • Psychosocial support is an important element in the follow-up of patients with oesophageal carcinoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / diagnosis. Esophageal Neoplasms / diagnosis. Practice Guidelines as Topic
  • [MeSH-minor] Combined Modality Therapy. Evidence-Based Medicine. Humans. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16970009.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 17
  •  go-up   go-down


17. Socinski MA: Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy. Clin Lung Cancer; 2004 Mar;5(5):274-89
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy.
  • Although the benefits of chemotherapy have been established for treating non-small-cell lung cancer (NSCLC), several clinical issues remain.
  • The optimal duration of therapy continues to be evaluated, and several agents have emerged for treating patients with recurrent advanced NSCLC.
  • Chemotherapy benefits for populations underrepresented in clinical trials, such as elderly patients and patients with poor performance status, also need to be established.
  • Although combination therapy with carboplatin/paclitaxel is one regimen of choice for treating advanced NSCLC, there may be ways to optimize its delivery schedule including use of weekly administration of paclitaxel and monthly administration of carboplatin.
  • In resectable stage IIIA disease, benefits of preoperative chemotherapy and chemotherapy/radiation therapy followed by surgery continue to be evaluated.
  • Although associated with esophageal toxicity, in non-resectable stage IIIA/IIIB disease, concurrent chemotherapy/radiation therapy has emerged as the schedule of choice.
  • Based on phase II studies, preoperative chemotherapy with or without radiation may benefit patients with early-stage disease, but studies have been inconclusive, yielding mixed results.
  • Recent trials of adjuvant chemotherapy following surgical resection in early-stage NSCLC have yielded conflicting results, with some trials showing no benefit to adjuvant therapy.
  • Trials under way will determine the future of adjuvant or induction chemotherapy in treating this patient population.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Staging
  • [MeSH-minor] Age Factors. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Clinical Trials as Topic. Combined Modality Therapy. Health Status. Humans. Neoplasm Recurrence, Local / drug therapy. Radiotherapy, Adjuvant


18. Ishibashi H, Ohta S, Hirose M, Matsunuma R, Tsuneizumi M, Nakagami K, Shibuya K, Tanio N, Nakajima N: [Mediastinal recurrence of breast cancer suspecting mediastinal fibrosis]. Kyobu Geka; 2006 Nov;59(12):1095-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 63-year-old female, who had undergone a modified radical mastectomy for breast cancer at the age of 45, was suffered from trachyphonia due to left recurrent nerve paralysis at the age of 53.
  • Computed tomography (CT) revealed mediastinal fibrosis, stenosis of esophagus and superior vena cava, and slight lymph nodes swelling.
  • She underwent mediastinal radiation and chemotherapy for mediastinal recurrence and stenting for esophageal stenosis.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / surgery. Mediastinal Diseases / etiology. Mediastinal Diseases / pathology. Mediastinum / pathology. Postoperative Complications
  • [MeSH-minor] Biopsy. Esophageal Stenosis / etiology. Esophageal Stenosis / therapy. Female. Fibrosis / etiology. Humans. Lymph Node Excision. Mastectomy, Modified Radical. Middle Aged. Stents. Thoracic Surgery, Video-Assisted

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094548.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Nishimura M, Daiko H, Yoshida J, Nagai K: Salvage esophagectomy following definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg; 2007 Nov;55(11):461-4; discussion 464-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage esophagectomy following definitive chemoradiotherapy.
  • OBJECTIVES: To evaluate the outcome of salvage surgery following definitive chemoradiotherapy (CRT) for locally advanced esophageal cancer.
  • METHODS: We reviewed patients undergoing salvage esophagectomy from August 2000 through April 2006 at the National Cancer Center Hospital East, following 5-fluorouracil and cisplatinum chemotherapy with concurrent radiotherapy over 50 Gy.
  • RESULTS: Forty-six patients (42 men, all with squamous cell carcinoma) underwent salvage surgery after full-dose concurrent chemoradiotherapy.
  • Operation time ranged from 257 to 602 min.
  • Postoperative complications were pneumonia in 5; anastmotic leakage in 10; wound infection in 3; anastomotic stenosis in 2; recurrent nerve palsy in 4; pyothorax in 2; multiple organ failure in 1; myocardial infarction in 1; trachea necrosis in 1.
  • The median survival time from salvage surgery was 12 months and that from CRT was 22 months.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 1997 Nov;114(5):811-5; discussion 816 [9375611.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Oct;126(4):1168-73 [14566264.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):337-41 [12607635.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Aug;124(2):270-7 [12167786.001]
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Jan;123(1):175-83 [11782772.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):425-33 [12957254.001]
  • (PMID = 18049854.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Kolh P, Honore P, Degauque C, Gielen J, Gerard P, Jacquet N: Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up. Eur J Cardiothorac Surg; 2000 Sep;18(3):293-300
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up.
  • METHODS: From January 1990 to December 1998, 130 patients underwent oesophageal resection for malignancy.
  • Indications were squamous cell carcinoma in 69 patients and adenocarcinoma in 61.
  • There were 84 subtotal oesophagectomies, with anastomosis in the neck in 44 patients and at the thoracic inlet in 40, and 46 distal oesophageal resections.
  • Postoperative complications occurred in 40 patients (31%), respectively, in ten (26%) and 30 (33%) patients after colonic and gastric transplants (P=0.48), and were pulmonary insufficiency or infection in 29 patients, anastomotic fistula in six, myocardial infarction in five, recurrent nerve palsy in four, renal insufficiency in three, and cerebrovascular accident in one.
  • The incidence of postoperative pulmonary complications was 70% (21/30 patients) in the subgroup who received preoperative radiochemotherapy, as compared to 11% (5/44 patients) in the subgroup of comparable staging, but without preoperative treatment (P<0.001).
  • Our results suggest that preoperative neoadjuvant treatment significantly increases postoperative pulmonary complications.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Colon / transplantation. Esophageal Neoplasms / surgery. Esophagus / surgery. Stomach / surgery
  • [MeSH-minor] Anastomosis, Surgical / methods. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagectomy. Female. Hospital Mortality. Humans. Male. Middle Aged. Palliative Care. Reoperation. Retrospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / surgery. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10973538.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


21. Takeda K, Nemoto K, Saito H, Ogawa Y, Takai Y, Yamada S: Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):626-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the factors associated with acute esophagitis in lung cancer patients treated with thoracic radiotherapy.
  • METHODS AND MATERIALS: We examined 35 patients with non-small-cell lung cancer (n = 27, 77%) and small-cell lung cancer (n = 8, 23%) treated with thoracic radiotherapy between February 2003 and November 2004.
  • The disease stage was Stage I in 2 patients (6%), Stage II in 1 (3%), Stage IIIa in 10 (28%), Stage IIIb in 9 (26%), and Stage IV in 9 (26%); 4 patients (11%) had recurrent disease after surgery.
  • A median dose of 60 Gy (range, 50-67 Gy) was given to the isocenter and delivered in single daily fractions of 1.8 or 2 Gy.
  • With heterogeneity corrections, the median given dose to the isocenter was 60.3 Gy (range, 49.9-67.2 Gy).
  • Of the 35 patients, 30 (86%) received concurrent chemotherapy consisting of a platinum agent, cisplatin or carboplatin, combined with paclitaxel in 18 patients (52%), irinotecan hydrochloride in 7 (20%), vincristine sulfate and etoposide in 2 (5%), vinorelbine ditartrate in 1 (3%), etoposide in 1 (3%), and docetaxel in 1 patient (3%).
  • Three of these patients underwent induction therapy with cisplatin and irinotecan hydrochloride, administered before thoracic radiotherapy, and concurrent chemotherapy.
  • Esophageal toxicity was graded according to the Radiation Therapy Oncology Group criteria.
  • The following factors were analyzed with respect to their association with Grade 1 or worse esophagitis by univariate and multivariate analyses: age, gender, concurrent chemotherapy, chemotherapeutic agents, maximal esophageal dose, mean esophageal dose, and percentage of esophageal volume receiving >10 to >65 Gy in 5-Gy increments.
  • RESULTS: Of the 35 patients, 25 (71%) developed acute esophagitis, with Grade 1 in 20 (57%) and Grade 2 in 5 (14%).
  • The most significant correlation was between esophagitis and percentage of esophageal volume receiving >35 Gy on univariate (p = 0.002) and multivariate (p = 0.018) analyses.
  • CONCLUSION: The percentage of esophageal volume receiving >35 Gy was the most statistically significant factor associated with mild acute esophagitis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Small Cell / radiotherapy. Esophagitis / etiology. Esophagus / radiation effects. Lung Neoplasms / radiotherapy. Radiation Injuries / etiology
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy Dosage. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936536.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Moghissi K, Dixon K, Thorpe JA, Stringer M, Moore PJ: The role of photodynamic therapy (PDT) in inoperable oesophageal cancer. Eur J Cardiothorac Surg; 2000 Feb;17(2):95-100
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of photodynamic therapy (PDT) in inoperable oesophageal cancer.
  • OBJECTIVE: To evaluate the role of PDT in palliation of patients with inoperable oesophageal cancer and to identify subgroups in which this role is of particular significance.
  • METHODS: Sixty-five patients (37 male, 28 female) aged 42-89 (mean 65.6) with advanced and inoperable oesophageal cancer were the subjects of this study.
  • Fifty-eight (89%) had previous treatments, other than PDT.
  • (1) Relief of dysphagia generally and specifically in those with cervical and post-cricoid carcinoma who were previously treated by external beam radiotherapy (EBR) (n=6) and those with previous intubation or stent (n=9);.
  • Three patients (4.6%) developed a mild skin photosensitivity reaction.
  • Survival was not significantly influenced by tumour histology, location in the oesophagus, severity of dysphagia on admission, or by previous therapy.
  • Survival was significantly influenced by Performance Status prior to treatment (P=0.03 log rank, for PS < or =2 vs. PS=3), an most significantly by the stage of the disease (P=0.0001 log rank, for Stage III vs. Stage IV).
  • CONCLUSIONS:. (1) PDT is safe and effective for palliation of dysphagia in inoperable oesophageal cancer.
  • This is particularly important in post-cricoid and cervical oesophageal cancer previously treated by other methods and for patients with recurrent malignant obstruction who previously had intubation or stent placement. (2) Survival is influenced by better PS (< or =2) and in those with disease Stage III rather than patients in Stage IV.
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Palliative Care. Photochemotherapy
  • [MeSH-minor] Aged. Deglutition Disorders / prevention & control. Dihematoporphyrin Ether / administration & dosage. Disability Evaluation. Female. Humans. Male. Neoplasm Staging. Porphyrins / administration & dosage. Prospective Studies. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10731642.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Porphyrins; 0 / polyhaematoporphyrin; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down






Advertisement